Inactive Instrument

Grindeks AS Stock Nasdaq Riga

GRD1R

LV0000100659

Pharmaceuticals

End-of-day quote Nasdaq Riga Other stock markets
- ^LVL	-

03/04/24	Grindeks Opens New Subsidiaries Worldwide	CI
24/02/21	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI

Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows: - research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.; - production of pharmaceutical active ingredients (5.1%). Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

03/04/24	Grindeks Opens New Subsidiaries Worldwide	CI
24/02/21	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI
22/01/21	SIA Liplat Holding completed the acquisition of additional 2.6% stake in Akciju sabiedriba Grindeks for €3.4 million.	CI
22/12/20	SIA Liplat Holding made an offer to acquire the remaining 5.84% stake in Akciju sabiedriba Grindeks for €7.6 million.	CI
26/11/20	Akciju Sabiedriba Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
27/08/20	Akciju Sabiedriba Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
18/08/20	Akciju sabiedriba Grindeks Approves to Pay Dividend, Payable on September 17, 2020	CI
04/08/20	Akciju sabiedriba Grindeks Proposes to Pay Dividend, Payable on September 17, 2020 and November 17, 2020, Respectively	CI
05/03/20	Grindeks Completes Phase 1 Clinical Study of its New Investigational Medicinal Product Methyl-GBB	CI
28/02/20	As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019	CI
04/02/20	JSC Grindeks Announces Appointment of Juris Hmelnickis as the Chairman of the Board	CI
22/01/20	JSC Grindeks Announces Resignation of Juris Bundulis as Chairman of the Board	CI
19/12/19	JSC Grindeks Receives A Certificate of Saudi Food and Drug Authority	CI

03/03/21	Grindeks : In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit	AQ
24/02/21	Grindeks : Andrejs Liberts appointed as the member of the board of JSC “Grindeks”	AQ
12/02/21	Grindeks : Delisting of AS „Grindeks” shares from the Baltic Main list	AQ
09/02/21	Grindeks : On exclusion of shares from the regulated market	AQ
26/01/21	Grindeks : Information about refusal to repurchase the final shares of JSC “Grindeks”	AQ

Manager	Title	Age	Since
Janis Romanovskis CEO	Chief Executive Officer	66	22/04/2010
Andrejs Liberts PRN	Corporate Officer/Principal	41	24/02/2021
Iveta Zomerfelde SAM	Sales & Marketing	-	03/03/2015

Director	Title	Age	Since
Kirovs Lipmans CHM	Chairman	85	01/01/2003
Anna Lipmane BRD	Director/Board Member	78	01/01/2008
Filips Lipmans BRD	Director/Board Member	48	01/01/2004

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.12%	-1.09%	+22.38%	+68.83%	48.92B
OTSUKA HOLDINGS CO., LTD.	-1.14%	+9.22%	+60.80%	+124.81%	41.53B
CIPLA LIMITED	-0.32%	-0.77%	-1.53%	+16.21%	12.43B
ZYDUS LIFESCIENCES LIMITED	+6.43%	+6.24%	+27.22%	+81.04%	11.7B
KRKA, D. D.	+0.77%	-0.38%	+30.98%	+137.44%	9.09B
GEDEON RICHTER	+1.95%	+9.30%	+24.43%	+40.59%	7.4B
ONO PHARMACEUTICAL CO., LTD.	+1.62%	+3.49%	+41.67%	-13.45%	7.15B
GLENMARK PHARMACEUTICALS LIMITED	+1.10%	+2.06%	+12.70%	+180.85%	6.66B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-1.22%	+7.23%	-25.51%	+28.75%	5.95B
Average	+1.01%	+3,738.12%	+21.46%	+73.90%	16.76B
Weighted average by Cap.	+0.34%	+5,024.23%	+30.58%	+83.06%

Grindeks AS Stock Nasdaq Riga

Stocks

GRD1R

LV0000100659

Pharmaceuticals

Latest news : Grindeks AS

Press Releases: Grindeks AS

Managers and Directors: Grindeks AS

Generic Pharmaceuticals

Company Profile